Proteolysis-Targeting Chimeras as Therapeutics and Tools for Biological DiscoveryGeorge M. Burslem(Yale University), Craig M. Crews(Yale University)CellJanuary 16, 202010.1016/j.cell.2019.11.031Cited by 1,002Open AccessFull TextSaveCiteExport RISWatch citationsAbstractRelated PapersLenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma CellsJan Krönke, Namrata D. Udeshi, Anupama Narla et al.|Science|2013|1.8kPhthalimide conjugation as a strategy for in vivo target protein degradationGeorg E. Winter, Dennis L. Buckley, Joshiawa Paulk et al.|Science|2015|1.7kCatalytic in vivo protein knockdown by small-molecule PROTACsDaniel P. Bondeson, Alina Mares, Ian E. Smith et al.|Nature Chemical Biology|2015|1.3kHijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4Jing Lü, Yimin Qian, Martha Altieri et al.|Chemistry & Biology|2015|1.1kValidation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemiaCatherine C. Smith, Qi Wang, Chen-Shan Chin et al.|Nature|2012|744